Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids

Journal of Pharmacy and Pharmacology

Volumn 57, Issue 12, 2005, Pages 1529-1537

  Jun, Seoung Wook ^a   Kim, Min Soo ^a   Jo, Guk Hyun ^a   Lee, Sibeum ^a   Woo, Jong Soo ^a   Park, Jeong Sook ^a   Hwang, Sung Joo ^a  

^a Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME AXETIL; HPMC 2910; HYDROXYPROPYLMETHYLCELLULOSE; POVIDONE DERIVATIVE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DIFFRACTION; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; HYDROGEN BOND; INFRARED SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; SOLID; SUPERCRITICAL FLUID; X RAY DIFFRACTION;

ANTI-BACTERIAL AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CEFUROXIME; CHROMATOGRAPHY, SUPERCRITICAL FLUID; HYDROGEN BONDING; MICROSCOPY, ELECTRON, SCANNING; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 28644450047     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.57.12.0003     Document Type: Article

References (38)

1. Beach, S., Latham, D., Sidgwick, C., Hanna, M., York, P. (1999) Control of the physical form of salmeterol xinafoate. Org. Process Res. Dev. 3: 370-376
2. 2 antisolvent with enhanced mass transfer. Int. J. Pharm. 228: 19-31
3. Chiou, W. L., Riegelman, S. (1971) Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60: 1281-1302
4. Craig, D. Q. M. (2001) The mechanisms of drug release from solid dispersions in water-soluble polymers. Int. J. Pharm. 231: 131-144
5. Crisp, H. A., Clayton, J. C. (1985) Amorphous form of cefuroxime ester, US Patent 4 562 181
6. Crisp, H. A., Clayton, J. C., Elliott, L. G., Wilson, E. M. (1989) Preparation of a highly pure, substantially amorphous form of cefuroxime axetil, US Patent 4 820 833
7. Dellamonica, P. (1994) Cefuroxime axetil. Int. J. Antimicrob. Agents 4: 23-36
8. Gosselin, P. M., Thibert, R., Preda, M., McMullen, D. N. (2003) Polymorphic properties of micronized carbamazepine produced by RESS. Int. J. Pharm. 252: 225-233
9. Hanna, M., York, P. (1993) Method and apparatus for the formation of particles, European Patent 93 13642 2
10. Juppo, A. M., Boissier, C., Khoo, C. (2003) Evaluation of solid dispersion particles prepared with SEDS. Int. J. Pharm. 250: 385-401
11. Khan, K. A. (1975) The concept of dissolution efficiency. J. Pharm. Pharmacol. 27: 48-49
12. Leuner, G., Dressman, J. (2000) Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50: 47-60
13. Lobenberg, R., Amidon, G. L. (2000) Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50: 3-12
14. Matson, D. W., Fulton, J. L., Petersen, R. C., Smith, F. D. (1987) Rapid expansion of supercritical fluid solutions: solute formation of powders, thin films, and fibers. Ind. Eng. Chem. Res. 26: 2298-2306
15. Matsumoto, T., Zografi, G. (1999) Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallization. Pharm. Res. 16: 1722-1728
16. Moneghini, M., Kikic, I., Voinovich, K., Perissutti, B., Filipovic-Grcic, J. (2001) Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterization, and in vitro dissolution. Int. J. Pharm. 222: 129-138
17. Moshashaee, S., Bisrat, M., Forbes, R. T., Nyqvist, H., York, P. (2000) Supercritical fluid processing of proteins. I: lysozyme precipitation from organic solution. Eur. J. Pharm. Sci. 11: 239-245
18. Oszczapowicz, I., Malafiej, E., Szelachowska, M., Horoszewicz-Malafiej, A., Kuklewicz, C., Sieranska, E., Denys, A., Niedworok, J. (1995a) Esters of cephalosporins, Part II. Differences in the properties of various forms of the 1-acetoxyethyl ester of cefuroxime. Acta. Polon. Pharm. Drug Res. 52: 397-401
19. Oszczapowicz, I., Malafiej, E., Horoszewicz-Malafiej, A., Szelachowska, M., Kuklewicz, C., Sieranska, E. (1995b) Esters of cephalosporins, Part III. Separation and properties of the R and S isomers of the 1-acetoxyethyl ester of cefuroxime. Acta. Polon. Pharm. Drug Res. 52: 471-476
20. Palakodaty, S., York, P., Pritchard, J. (1998) Supercritical fluid processing of materials from aqueous solutions: the application of SEDS to lactose as a model substance. Pharm. Res. 15: 1835-1843
21. Powell, D. A, James, N. C., Ossi, M. J., Nahata, M. C., Donn, K. H. (1991) Pharmacokinetics of cefuroxime axetil suspension in infants and children. Antimicrob. Agents. Chemother. 35: 2042-2045
22. Reverchon, E., Della Porta, G., Trolio, A. D., Pace, S. (1998) Supercritical antisolvent precipitation of nanoparticles of superconductor precursors. Ind. Eng. Chem. Res. 37: 952-958
23. Reverchon, E., De Macro, I., Della Porta, G. (2002) Tailoring of nano- and micro-particles of some superconductor precursors by supercritical antisolvent precipitation. J. Supercrit. Fluids 23: 81-87
24. Sasinowska, M., Winiewska, I., Gumulka, W., Oszczapowicz, I., Szelachowska, M., Interewiez, B. (1995) Esters of cephalosporins, Part I. Permeability of cefuroxime liberated from its 1-acetoxyethyl ester through biological membranes; influence of the form and size of the ester particles. Acta. Polon. Pharm. Drug Res. 52: 397-401
25. Sekikawa, H., Nakano, M., Arita, T. (1978) Inhibitory effect of polyvinylpyrrolidone on the crystallization of drugs. Chem. Pharm. Bull. 26: 118-126
26. Sekikawa, H., Nakano, M., Arita, T. (1979) Dissolution mechanisms of drug-polyvinylpyrrolidone coprecipitates in aqueous solution. Chem. Pharm. Bull. 27: 1223-1230
27. Serajuddin, A. T. M. (1999) Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88: 1058-1066
28. Simonelli, A. P., Mehta, S. C., Higuchi, W. I. (1976) Dissolution rates of high energy sulfathiazole-povidone coprecipitates. II: characterization of form of drug controlling its dissolution rate via solubility studies. J. Pharm. Sci. 65: 355-361
29. Taylor, L. S., Zografi, G. (1997) Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm. Res. 14: 1691-1698
30. Turk, M., Hils, P., Helfgen, B., Schaber, K., Martin, H. J., Wahl, M. A. (2002) Micronization of pharmaceutical substances by the Rapid Expansion of Supercritical Solutions (RESS): a promising method to improve bioavailability of poorly soluble pharmaceutical agents. J. Supercrit. Fluids 22: 75-84
31. US Pharmacopoeia XXVI (USP26) (2002) Official Monographs: Cefuroxime Axetil Tablets. US Pharmacopoeia Convention, Rockville, MD, pp 388-389
32. Van den Mooter, G., Augustijns, P., Blaton, N., Kinget, R. (1998) Physico-chemical characterization of solid dispersions of temazepan with polyethylene glycol 6000 and PVP K30. Int. J. Pharm. 164: 67-80
33. Van den Mooter, G., Wuyts, M., Blaton, N., Busson, R., Grobet, P., Augustijns, P., Kinget, R. (2001) Physical stabilization of amorphous ketoconazole in solid dispersions with polyvinyl-pyrrolidone K25. Eur. J. Pharm. Sci. 12: 261-269
34. Won, D. H., Kim, M. S., Lee, S., Park, J. S., Hwang, S. J. (2005) Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int. J. Pharm. 301: 199-208
35. Woo, J. S., Chang, H. C. (2000) Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof, US Patent 6 107 290
36. Woo, J. S., Chang, H. C., Lee, C. H. (2002) Preparation and evaluation of non-crystalline cefuroxime axetil solid dispersion. J. Kor. Pharm. Sci. 32: 73-80
37. Yeo, S. D., Kim, M. S., Lee, J. C. (2003) Recrystallization of sulfathiazole and chlorpropamide using the supercritical fluid antisolvent process. J. Supercrit. Fluids 25: 143-154
38. Yoshioka, M., Hancock, B. C., Zografi, G. (1995) Inhibition of indomethacin crystallization in polyvinylpyrrolidone coprecipitates. J. Pharm. Sci. 84: 983-986